GT Biopharma

GT Biopharma Current Assets

The Current Assets of GT Biopharma (GTBP) as of Oct 23, 2026 is 8.11 M USD. In the previous year, Current Assets was 4.23 M USD — a change of 91.54% (higher).

Current Assets

8.11 MUSD

YoY

91.54%

Last updated:

Current Assets of GT Biopharma is 2025 8.11 M USD. Current Assets of GT Biopharma was 2024 4.23 M USD. It decreases by 91.54% higher compared to the previous year.

The GT Biopharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
90,000.00 USD
Jan 1, 2019
274,000.00 USD
Jan 1, 2020
5.66 M USD
Jan 1, 2021
32.17 M USD
Jan 1, 2022
16.56 M USD
Jan 1, 2023
14.06 M USD
Jan 1, 2024
4.23 M USD
Jan 1, 2025
8.11 M USD
The GT Biopharma Current Assets history
YEARCurrent AssetsYoY
8.11 MUSD+91.54%
4.23 MUSD-69.89%
14.06 MUSD-15.13%
16.56 MUSD-48.52%
32.17 MUSD+468.26%
5.66 MUSD+1,966.06%
274,000.00USD+204.44%
90,000.00USD-84.38%
576,000.00USD+2,642.86%
21,000.00USD-57.14%
49,000.00USD-94.70%
924,000.00USD+1,026.83%
82,000.00USD+3.80%
79,000.00USD-24.04%
104,000.00USD-24.09%
137,000.00USD-91.14%
1.55 MUSD+511.07%
253,000.00USD-86.97%
1.94 MUSD-65.94%
5.70 MUSD+4.78%
5.44 MUSD-27.84%
7.54 MUSD+613.34%
1.06 MUSD+0.57%
1.05 MUSD+48.87%
706,000.00USD-81.96%
3.91 MUSD+21.33%
3.23 MUSD-40.19%
5.39 MUSD+3.47%
5.21 MUSD+152.84%
2.06 MUSD-26.39%
2.80 MUSD+6.06%
2.64 MUSD-7.43%
2.85 MUSD-38.71%
4.65 MUSD+2.11%
4.56 MUSD-7.77%
4.94 MUSD+16.15%
4.25 MUSD+34.79%
3.16 MUSD+12.39%
2.81 MUSD-2.47%
2.88 MUSD+1.70%
2.83 MUSD-15.74%
3.36 MUSD+7.45%
3.13 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GT Biopharma Stock analysis

What does GT Biopharma do? GT Biopharma Inc, based in Brisbane, California, is a clinical-stage biopharmaceutical company operating in the Health Care sector. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE NK cell engager platform, which enhances natural killer cells to target cancer. It employs two full-time staff and is listed on the stock market since October 22, 2013. Its lead product, GTB-3550, is a tri-specific fusion protein for CD33-expressing cancers, currently in Phase 1 clinical trials. GT Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GT Biopharma stock

Current Assets of GT Biopharma is 8.11 M USD in 2025.

Current Assets of GT Biopharma changed from 4.23 M USD to 8.11 M USD, representing a 91.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets GT Biopharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's GT Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GT Biopharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GT Biopharma